Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05431088 · ClinicalTrials.gov registry record · Phase 2
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
A Phase 2 study of Sickle Cell Disease, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 389
- Enrollment target
- 20
- Study locations
NCT05431088 is a Phase 2 study of Sickle Cell Disease that is actively recruiting participants, run by Pfizer. The registered enrollment target is 389 participants, above the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT05431088, a Phase 2 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 389 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.
Conditions Studied
Interventions
- DRUG Osivelotor
Study Locations (20)
Louisiana
- LSU Health Baton Rouge-North Clinic - Baton Rouge
- Our Lady of the Lake Hospital, Inc. - Baton Rouge
- Our lady of the Lake Hospital - Baton Rouge
- University Medical Center New Orleans - New Orleans
North Carolina
- Clinical & Translational Research Center (CTRC) - Chapel Hill
- UNC Health - Chapel Hill
- UNC Eastowne Medical Office Building - Consent Only - Chapel Hill
- UNC IDS - Morrisville
Florida
- Edward Jenner Research Group Center LLC - Plantation
- Pediatric Hematology / Oncology a division of Kidz Medical services - West Palm Beach
- St. Mary's Medical Center - West Palm Beach
Illinois
- University of Illinois at Chicago Clinical Research Center - Chicago
- University of Illinois Hospital and Health Sciences System - Investigational Drug Services (IDS) - Chicago
- University of Illinois Hospital and Health Sciences System - Chicago
Georgia
- Alpha Clinical Research Georgia - Dunwoody
- Sonar Clinical Research - Riverdale
Connecticut
- Smilow Cancer Hospital - New Haven
Mississippi
- Mississippi Center for Advanced Medicine - Madison
Missouri
- University Health - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2032-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05431088
The ClinicalTrials.gov registry entry for NCT05431088 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 389 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (34% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Osivelotor is the first listed.
NCT05431088 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Louisiana, North Carolina, Florida.
Frequently Asked Questions
What is clinical trial NCT05431088 about?
NCT05431088 is a clinical study titled "A Phase 2/3 Study in Adult and Adolescent Participants With SCD". The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.
What is the current status of trial NCT05431088?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 389 participants. The study started on 2022-09-22. Estimated completion is 2032-12-31.
What conditions does trial NCT05431088 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT05431088?
The interventions under investigation include: Osivelotor (DRUG).
Who is sponsoring clinical trial NCT05431088?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05431088 being conducted?
This trial has 20 study locations across Connecticut, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
-
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.